These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 10346546)
1. GP IIb/IIIa inhibitors: an evidence-based approach to their use. Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546 [No Abstract] [Full Text] [Related]
2. Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction. Ben-Yehuda O J Am Coll Cardiol; 2006 Feb; 47(3):538-40. PubMed ID: 16458132 [No Abstract] [Full Text] [Related]
4. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. Glaser R; Glick HA; Herrmann HC; Kimmel SE J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes. Boersma E J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743 [No Abstract] [Full Text] [Related]
6. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
7. Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice. Young JJ; Kereiakes DJ J Interv Cardiol; 2002 Apr; 15(2):115-20. PubMed ID: 12063806 [No Abstract] [Full Text] [Related]
8. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. McCollam PL; Foster DA; Riesmeyer JS Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921 [TBL] [Abstract][Full Text] [Related]
10. [Role of GP IIb/IIIa blockers in clinical cardiology]. Rossi ML; Merlini PA Recenti Prog Med; 2003 Oct; 94(10):440-3. PubMed ID: 14619191 [TBL] [Abstract][Full Text] [Related]
11. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. Tcheng JE Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231 [No Abstract] [Full Text] [Related]
12. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466 [TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Young JJ J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003 [No Abstract] [Full Text] [Related]
15. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists]. Araujo R; Agustí A Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849 [No Abstract] [Full Text] [Related]
16. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912 [No Abstract] [Full Text] [Related]
17. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Subbarao VD; Phillips J; Stouffer GA Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570 [TBL] [Abstract][Full Text] [Related]